News
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Engages the University of Alberta and Cross Cancer Institute to Expand PNKP Inhibitor Research into Hard-to-Treat Cancers
Onco-Innovations partners with University of Alberta and Cross Cancer Institute for preclinical study focusing on hard-to-treat cancers, starting with glioblastoma. Research led by Dr. Michael Weinfeld -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations' Inka Health to Launch Global AI-Oncology Consortium to Advance Predictive Cancer Research
Onco-Innovations Limited's subsidiary, Inka Health Corp., launches PROmAI Consortium for AI in oncology to enhance predictive modeling and collaboration among key stakeholders -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
Onco-Innovations announces commencement of manufacturing for preclinical testing of nanoparticle-formulated PNKP inhibitor technology in collaboration with Dalton Pharma Services -
